Jupiter Asset Management Ltd. Buys 181,093 Shares of Aurinia Pharmaceuticals Inc $AUPH
Jupiter Asset Management Ltd. increased its stake in Aurinia Pharmaceuticals by 24.1% in Q2, owning 933,862 shares worth $7.91 million. Analysts have mixed ratings on AUPH, with a consensus "Hold" and target price of $17.67. The stock opened at $15.22, with a market cap of $2.01 billion. Aurinia reported Q3 EPS of $0.23, beating estimates, and revenue of $73.47 million. The company focuses on therapies for unmet medical needs, offering LUPKYNIS for lupus nephritis.
Jupiter Asset Management Ltd. increased its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 24.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 933,862 shares of the biotechnology company's stock after purchasing an additional 181,093 shares during the quarter. Jupiter Asset Management Ltd. owned 0.71% of Aurinia Pharmaceuticals worth $7,910,000 at the end of the most recent quarter.
- These 2 Healthcare Stocks Have Doubled in 2023
Other hedge funds and other institutional investors also recently bought and sold shares of the company. MAI Capital Management bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $39,000. Xponance Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth about $82,000. Kazazian Asset Management LLC bought a new position in Aurinia Pharmaceuticals during the 1st quarter valued at about $84,000. Mackenzie Financial Corp purchased a new stake in Aurinia Pharmaceuticals in the 1st quarter worth about $86,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Aurinia Pharmaceuticals in the 2nd quarter worth about $92,000. Hedge funds and other institutional investors own 36.83% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on AUPH shares. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Bloom Burton downgraded Aurinia Pharmaceuticals from a "moderate buy" rating to a "hold" rating in a research report on Wednesday, November 5th. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a "hold" rating to a "buy" rating and increased their target price for the stock from $10.00 to $21.00 in a research note on Friday, November 7th. Royal Bank Of Canada reissued a "sector perform" rating and set a $15.00 target price (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $17.67.
Check Out Our Latest Stock Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Performance
AUPH opened at $15.22 on Friday. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 12-month low of $6.55 and a 12-month high of $16.20. The firm has a 50 day moving average of $12.54 and a two-hundred day moving average of $10.37. The firm has a market capitalization of $2.01 billion, a PE ratio of 35.40 and a beta of 1.30.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.16 by $0.07. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $67.70 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.
Aurinia Pharmaceuticals Profile
(Free Report)Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Articles
- Five stocks we like better than Aurinia Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing
- How to Read Stock Charts for Beginners
- Ondas Holdings Signals a Rebound as Drone Demand Soars
- Dividend Payout Ratio Calculator
- Disney’s 2026 Outlook Brightens Under Iger's Magic Touch
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Aurinia Pharmaceuticals Right Now?
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
